Halozyme Therapeutics Stock Current Asset
| HALO Stock | USD 48.20 0.27 0.56% |
Halozyme Therapeutics fundamentals help investors to digest information that contributes to Halozyme Therapeutics' financial success or failures. It also enables traders to predict the movement of Halozyme Stock. The fundamental analysis module provides a way to measure Halozyme Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Halozyme Therapeutics stock.
As of the 29th of November 2024, Total Current Assets is likely to grow to about 783.7 M. Also, Non Current Assets Total is likely to grow to about 1 B. Halozyme | Current Asset |
Halozyme Therapeutics Company Current Asset Analysis
Halozyme Therapeutics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Halozyme Therapeutics Current Asset | 171.77 M |
Most of Halozyme Therapeutics' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Halozyme Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Halozyme Current Asset Historical Pattern
Today, most investors in Halozyme Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Halozyme Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Halozyme Therapeutics current asset as a starting point in their analysis.
Halozyme Therapeutics Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Halozyme Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Halozyme Therapeutics has a Current Asset of 171.77 M. This is 92.02% lower than that of the Biotechnology sector and 83.8% lower than that of the Health Care industry. The current asset for all United States stocks is 98.16% higher than that of the company.
Halozyme Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Halozyme Therapeutics' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Halozyme Therapeutics could also be used in its relative valuation, which is a method of valuing Halozyme Therapeutics by comparing valuation metrics of similar companies.Halozyme Therapeutics is currently under evaluation in current asset category among its peers.
Halozyme Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Halozyme Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Halozyme Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Halozyme Fundamentals
| Return On Equity | 1.12 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.41 % | ||||
| Operating Margin | 0.56 % | ||||
| Current Valuation | 7 B | ||||
| Shares Outstanding | 127.23 M | ||||
| Shares Owned By Insiders | 1.07 % | ||||
| Shares Owned By Institutions | 98.93 % | ||||
| Number Of Shares Shorted | 10.45 M | ||||
| Price To Earning | 60.08 X | ||||
| Price To Book | 13.62 X | ||||
| Price To Sales | 6.51 X | ||||
| Revenue | 829.25 M | ||||
| Gross Profit | 454.2 M | ||||
| EBITDA | 451.95 M | ||||
| Net Income | 281.59 M | ||||
| Cash And Equivalents | 209.36 M | ||||
| Cash Per Share | 1.52 X | ||||
| Total Debt | 1.5 B | ||||
| Debt To Equity | 4.28 % | ||||
| Current Ratio | 2.72 X | ||||
| Book Value Per Share | 3.56 X | ||||
| Cash Flow From Operations | 388.57 M | ||||
| Short Ratio | 6.62 X | ||||
| Earnings Per Share | 3.02 X | ||||
| Price To Earnings To Growth | (2.50) X | ||||
| Target Price | 62.44 | ||||
| Number Of Employees | 373 | ||||
| Beta | 1.29 | ||||
| Market Capitalization | 6.17 B | ||||
| Total Asset | 1.73 B | ||||
| Retained Earnings | 90.55 M | ||||
| Working Capital | 633.93 M | ||||
| Current Asset | 171.77 M | ||||
| Current Liabilities | 62.46 M | ||||
| Net Asset | 1.73 B |
About Halozyme Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Halozyme Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Halozyme Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Halozyme Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Halozyme Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Halozyme Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Halozyme Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Halozyme Stock
Moving against Halozyme Stock
| 0.6 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.59 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.58 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.47 | GANX | Gain Therapeutics | PairCorr |
| 0.44 | GILD | Gilead Sciences | PairCorr |
The ability to find closely correlated positions to Halozyme Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Halozyme Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Halozyme Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Halozyme Therapeutics to buy it.
The correlation of Halozyme Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Halozyme Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Halozyme Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Halozyme Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Halozyme Therapeutics Piotroski F Score and Halozyme Therapeutics Altman Z Score analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.721 | Earnings Share 3.02 | Revenue Per Share 7.431 | Quarterly Revenue Growth 0.343 | Return On Assets 0.1487 |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.